Literature DB >> 16241949

Urokinase induced fibrinolysis in thromboelastography: a model for studying fibrinolysis and coagulation in whole blood.

M J Gallimore1, S L Harris, K A Tappenden, M Winter, D W Jones.   

Abstract

BACKGROUND: The contact system (CS) proteins, factor XII and prekallikrein are thought to have roles in blood coagulation and fibrinolysis. Recent research has suggested that the CS proteins might be more important in fibrinolysis and cell function than in coagulation. Most studies on fibrinolysis have used plasma or euglobulin assays, ignoring the influence of cellular elements of blood on the fibrinolytic process. OBJECTIVE AND METHODS: In order to study both coagulation and fibrinolysis in whole blood (WB), we have developed a thromboelastography (TEG) assay to investigate both coagulation and fibrinolysis in the same blood sample. In this assay, named urokinase (UK) induced fibrinolysis in thromboelastography (UKIFTEG), TEG is performed on recalcified citrated WB in the presence of UK. Large variations in Ly60 (percentage lysis 60 min after clot formation) were obtained between different donors with the same UK concentration. The UKIFTEG assay was therefore performed using UK concentrations that gave Ly60 values in the approximate range of 20-40%.
RESULTS: The effect of CS activation was investigated in the presence or absence of celite (10 mg mL(-1) blood). Celite shortened the clotting time (CT), and increased Ly60 values. Factor XIIa (FXIIa) and plasma kallikrein (KK) produced concentration dependent reductions in CT (significant at concentrations of 1303 and 2600 ng mL(-1) blood, respectively) and increased Ly60 values (significant at concentrations of 652 and 1300 ng mL(-1) blood, respectively).
CONCLUSIONS: Our results show that CS activation and both FXIIa and KK produce reductions in clotting time and enhanced fibrinolysis in UKIFTEG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16241949     DOI: 10.1111/j.1538-7836.2005.01615.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1.

Authors:  Jerzy Jankun; Ewa Skrzypczak-Jankun
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

2.  Toll-like receptor 9 signaling is critical for early experimental deep vein thrombosis resolution.

Authors:  Peter K Henke; Mayo Mitsuya; Catherine E Luke; Megan A Elfline; Joseph F Baldwin; K Barry Deatrick; Jose A Diaz; Vikram Sood; Gilbert R Upchurch; Thomas W Wakefield; Cory Hogaboam; Steven L Kunkel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-10-21       Impact factor: 8.311

3.  Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.

Authors:  Khaled Shahrour; Rick Keck; Jerzy Jankun
Journal:  Biomed Res Int       Date:  2015-03-26       Impact factor: 3.411

4.  Don't let D-dimer fool you: Elevated D-dimer plasma levels should not imply 'hyperfibrinolysis'.

Authors:  M Hardy; M Bareille; T Lecompte; F Mullier
Journal:  Thromb Res       Date:  2022-04-25       Impact factor: 10.407

5.  Assessment of Fibrinolysis in Sepsis Patients with Urokinase Modified Thromboelastography.

Authors:  Mauro Panigada; Lucia Zacchetti; Camilla L'Acqua; Massimo Cressoni; Massimo Boscolo Anzoletti; Rossella Bader; Alessandro Protti; Dario Consonni; Armando D'Angelo; Luciano Gattinoni
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

6.  Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity.

Authors:  Gerhardus J A J M Kuiper; Marie-Claire F Kleinegris; René van Oerle; Henri M H Spronk; Marcus D Lancé; Hugo Ten Cate; Yvonne M C Henskens
Journal:  Thromb J       Date:  2016-01-14

Review 7.  Precision Treatment in ACS-Role of Assessing Fibrinolysis.

Authors:  Ying X Gue; Young-Hoon Jeong; Mohamed Farag; Nikolaos Spinthakis; Diana A Gorog
Journal:  J Clin Med       Date:  2021-03-01       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.